We investigated polymorphisms of cytochrome P450 2A6 (CYP2A6) and its association with smoking habits in 412 healthy Brazilians, self-recognized as white (n ¼ 147), black (n ¼ 123) and intermediate (n ¼ 142), and classified as smokers (n ¼ 205, including 61 ex-smokers) and nonsmokers (n ¼ 207). The frequencies of the variant alleles CYP2A6*1B, CYP2A6*2, CYP2A6*4 and CYP2A6*9 in the overall study population were 29.9, 1.7, 0.5 and 5.7%, respectively. Significant differences in the CYP2A6 allelic distribution were observed across the three population subgroups. There was a statistically significant trend for decreasing frequency of CYP2A6*1B from white to intermediate and to black persons. An association between CYP2A6 genotype and smoking dependence was detected, which could not be explained by the expected phenotypic activity of CYP2A6. In white and intermediate persons, the odds ratio (OR) of being smokers vs nonsmokers was 0.07 (95% CI 0.02-0.20; Po0.001) and 0.27 (95% CI 0.12-0.61; Po0.001), respectively, for genotypes including allele CYP2A6*1B, as compared to wild-type homozygous. In contrast, the corresponding OR in black Brazilians was 1.34 (95% CI 0.57-3.17; P ¼ 0.46). These data suggest that the CYP2A6*1B is associated with smoking dependence in white and intermediate, but not black Brazilians.
INTRODUCTION
Despite decades of intensive tobacco control efforts, a substantial proportion of the world population continues to smoke. The World Health Organization lists smoking as the main cause of avoidable death around the world, and predicts that the number of premature deaths caused by tobacco use will approach 10 million per year in the early 2020s. 1 Smoking behavior is influenced by both environmental and genetic factors, [2] [3] [4] the latter affecting initiation, continuation and cessation of smoking. 5 Estimated inheritability rates are 50-84% for smoking initiation and 70-86% for persistence and amount. 5, 6 Of the hundreds of chemicals present in tobacco products, such as carbon monoxide, alkaloids, tar and nitrosamines, 5 nicotine is the primary culprit of tobacco dependence, 7 Addicted smokers adjust their smoking to maintain constant blood and brain nicotine levels, 8 against the drug's elimination from the body, which occur mainly through C-oxidation to the inactive metabolite cotinine. The cytochrome P450 (CYP) 2A6 is the major enzyme catalyzing this reaction [9] [10] [11] as well as the subsequent conversion of cotinine into 3 0 -hydroxicotinine. 12 The catalytic activity of CYP2A6 displays large interindividual differences due to polymorphisms in the CYP2A6 gene. 13 The role of CYP2A6 polymorphism in smoking behavior is a topic of active investigation, and evidence has been presented that individuals with extra copies of the CYP2A6 gene compensate for the increased nicotine metabolism by inhaling their cigarettes with greater intensity. 14 On the other hand, individuals who have one or two inactive CYP2A6 alleles have been reported to start smoking at a later age, to smoke for shorter periods of time, to be more likely to quit 14, 15 and to smoke fewer cigarettes than individuals homozygous for the wild-type CYP2A6 allele. 14, 16 Some of these observations, however, have not been consistently confirmed. 17, 18 The postulated role of CYP2A6 polymorphism on tobacco habits plus the availability of a large number of subjects enrolled in tobacco cessation programs at the Instituto Nacional de Câncer (INCA)-which is responsible for establishing national policies of cancer control and prevention in Brazil-prompted the present study, which has two major objectives: first, to determine, in a sample of the Brazilian population, the frequencies of four variant CYP2A6 alleles, namely CYP2A6*1B (gene conversion in the 3 0 -flanking region), CYP2A6*2, CYP2A6*4 and CYP2A6*9, which together with the wild-type allele (CYP2A6*1A) represent ca. 90% in other populations studied to date. [19] [20] [21] [22] The second purpose of this study was to investigate whether CYP2A6 polymorphisms are associated with individual susceptibility to smoking dependence.
MATERIAL AND METHODS

Subjects
The study protocol was approved by INCA's Ethics Committee and written informed consent was obtained from the participating subjects, who were recruited at the institute's blood bank and programs for tobacco control. Blood samples were obtained from 412 unrelated Brazilians (219 men, 193 women), aged 18-63 years, who agreed to participate in this study. The subjects answered a questionnaire about their ancestry, demographics and smoking habits. The pronounced level of admixture in the trihybrid Brazilian population, with Amerindian, European and African roots, poses special challenges to ethnic classifications in this population. In this study, we adopted the classification scheme used in the 2000 Brazilian population Census, 23 which relies on self-definition of skin color. The term color ('cor' in Portuguese language) is preferred to race in Brazil, probably because it captures the continuous aspects of phenotypes and also because a racial descent rule is not operational in this country, in contrast to others, for example, the United States. 24, 25 The percent distribution of the study population in the three subgroups was 35.7% white, 29.8% black and 34.5% 'intermediate'.
With regard to smoking habits, the subjects were classified as (i) smokers (n ¼ 205), including both current smokers (n ¼ 144, those who have been smoking at least two cigarettes a day for the past 6 months) and ex-smokers (n ¼ 61, those who had stopped smoking for at least 6 months) and (ii) nonsmokers, who had never smoked regularly (n ¼ 207).
CYP2A6 Genotyping
Genomic DNA was extracted from peripheral lymphocytes by using a GFXt Genomic Blood DNA Purification Kit (Amersham-Pharmacia Biotech Inc., USA). Approximately 50 ng of each DNA sample was subjected to allele-specific polymerase chain reactions (PCR). The subjects were genotyped for a 3 0 UTR gene conversion (see below), CYP2A6*2 (1799T4A) and CYP2A6*4 (gene deleted) alleles using methods described by Goodz and Tyndale, 26 and CYP2A6*9 (À48T4G), using the method developed by Schoedel et al. 27 After conclusion of the present study, a novel CYP2A6 mutation (À1013A4G SNP in the 5 0 -flanking region) was reported, 28 and the allele previously named CYP2A6*1B has been redefined as having both the 3 0 UTR gene conversion and a G at position À1013. 13 Accordingly, the gene conversion in the 3 0 -flanking region, which we examined, occurs in alleles *1B, *1C and *1E, but as the latter two are quite rare (o1.5%) in the populations studied to date, we chose to keep the nomenclature *1B for the alleles having the 3 0 UTR gene conversion. For the detection of the CYP2A6*9 allele, the first PCR was performed with the primers 2A65Pr1F (5 0 -ACC TAG ACT TAA TCT TCC CGT ATA C-3 0 ) and 2A6In1R (5 0 -CCC AAG ATC CTG TCT TTC TGA T-3 0 ). The second allele-specific PCR was performed with the primers 2A6-460F (5 0 -ATC CTC CAC AAC AGA AGA CCC CTA A-3 0 ) and 2A6-17RA (5 0 -ACG GCT GGG GTG GTT TGC CTT TA-3 0 ) or 2A6-17RC (5 0 -ACG GCT GGG GTG GTT TGC CTT TC-3 0 ). The first reaction mixture contained 1 Â PCR buffer (MBI Fermentas, USA), 1.2 mM magnesium chloride, 200 mM dNTPs (Amersham-Pharmacia Biotech Inc., USA), 0.16 mM of each primer and 2 U of Taq DNA polymerase (Fermentas) in a final volume of 25 ml. After an initial denaturation at 941C for 1 min, the amplification was performed by denaturation at 941C for 20 s, annealing at 621C for 30 s and extension at 721C for 2 min, for 30 cycles. An aliquot 1 ml of the PCR product was used in two parallel reactions that are performed using combinations of primers consisting of a common forward primer and allele-specific reverse primers selective for either the *1A allele, allowing amplification of the wild-type CYP2A6 gene as a positive control and/or the variant allele *9. The reactions mixture contained 1 Â PCR buffer, 1.0 mM magnesium chloride, 100 mM dNTPs, 0.16 mM of each primer and 0.5 U of Taq DNA polymerase in a final volume of 25 ml. After an initial denaturation at 941C for 1 min, the amplification was performed by denaturation at 941C for 20 s, annealing at 681C for 40 s and extension at 721C for 1 min, for 16 cycles. An aliquot of the PCR product, 20 ml, was analyzed by electrophoresis with 1.2% agarose gel stained with ethidium bromide.
Statistical Analysis
Allele frequencies were derived by gene counting. The Fisher exact method, in the Fisher-Freeman-Halton format, 29 was used for comparisons of CYP2A6 allele and genotype distributions across the population subgroups. The 95% confidence intervals (95% CI) were used for pair-wise comparisons of allele frequencies between the study subgroups. In addition, the Jonckheere-Terpstra test was used for investigating trends across these subgroups. The chisquare (w 2 ) test for goodness-of-fit was used to check whether the distribution of CYP2A6 genotypes in the overall population and in each subgroup deviated from the HardyWeinberg equilibrium (HWE). The influence of CYP2A6 *1B on smoking dependence was evaluated by comparing the odds ratio (OR) between smokers and nonsmokers, for each study subgroup. For this analysis, heterozygotes (*1A/*1B) and homozygotes (*1B/*1B) were grouped in one single class. The software packages StatXact-5 and Egret version 2.0.3 (CYTEL Software Corp., Cambridge, MA, USA) were used for statistical analysis of the data and the level of significance was set at Po0.05. Table 1 shows the distribution of the study population in the three subgroups and according to smoking status, while Table 2 presents the CYP2A6 allele frequencies in the enrolled subjects. The variant allele frequency detected in the overall study population was 37.8%, with alleles CYP2A6*1B, *2, *4 and *9 accounting for 29.9, 1.7, 0.5 and 5.7%, respectively, of the total allele count. Significant differences in the CYP2A6 allelic distribution were observed across the three population subgroups (Po0.0002, Fisher's exact test). When pair-wise comparisons were made, the only instance in which the 95% CIs for variant alleles did not overlap was in relation to CYP2A6*1B in white vs black Brazilians. In addition, a statistically significant trend for decreasing frequency of allele CYP2A6*1B across the study subgroups was observed (Po0.0001, Jonkheere-Tersptra test). Comparison of the variant allele frequencies in Brazilians with those reported for other populations (Table  2) shows that the 95% CIs for CYP2A6*1B, *2, *4 and *9 in white Brazilians overlap the values reported for European and North-American Caucasians. The same situation was observed between black Brazilians and African-Americans.
RESULTS
The CYP2A6 genotype frequencies in the study population are shown in Table 3 . Neither CYP2A6*2 homozygotes Nakajima et al.
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CYP2A6 polymorphisms and smoking in Brazilians GM Vasconcelos et al nor CYP2A6*1B/*2, CYP2A6*1B/*4, CYP2A6*2/*4, CYP2A6*2/*9 or CYP2A6*4/*9 heterozygotes were found in the study population. The genotype frequencies for the overall population deviated from the HWE, whether the data were analyzed as presented in Table 3 (w 2 ¼ 81.6, Po0.0001) or after grouping genotypes with observed frequencies lower than 2% in one single class (w 2 ¼ 39.0, Po0.0001). The genotype frequencies for the white and intermediate, but not for the black, subgroups deviated from the HWE ( Table 3) .
The distribution of the CYP2A6 genotype frequencies according to smoking status is displayed in Table 4 . The results are presented for the overall population, because several genotypes were absent or at low frequencies (o1%) in one of more population subgroups. Statistical analysis rejected the hypothesis of no association between genotype frequency and smoking status, whether smokers (current plus ex-smokers) were compared with nonsmokers (w 2 ¼ 37.7; Po0.0001) or current smokers, ex-smokers and nonsmokers were compared (w 2 ¼ 57.6; Po0.0001). To investigate further the association of CYP2A6 polymorphisms with smoking habits, the genotypes were classed according to the expected activity of the CYP2A6 enzyme: defective, including two copies of allele *4; reduced, including one copy of defective alleles *2 and *4 or at least one copy of the reduced-activity allele *9 and normal, including *1A and *1B alleles. The Fisher exact test revealed no difference among the genotypes included in the reduced activity class with regard to smoking habits (FI(X) ¼ 6.45; P ¼ 0.16). In contrast, a statistically significant difference was observed in the normal activity class between smokers (current plus exsmokers) and nonsmokers (FI(X) ¼ 29.9; Po0.0001), as well as across current smokers, ex-smokers and nonsmokers (FI(X) ¼ 29.6; Po0.0001). In view of these results, the normal activity class was subdivided, as shown in Table 5 , and the association between genotype frequency and smoking status was tested. The results indicated significantly more carriers of the CYP2A6*1B allele in nonsmokers than in smokers, whether smokers (current plus ex-smokers) were compared with nonsmokers (w 2 ¼ 26.3; Po0.0001) or current smokers, ex-smokers and nonsmokers were compared (w 2 ¼ 27.4; Po0.0001). To assess the influence of CYP2A6 *1B on smoking dependence, the OR of being smoker vs non-smoker was calculated for each population subgroup. The results (Table  6 ) indicated that the OR for genotypes with one or two copies of CYP2A6*1B, as compared to wild-type homozygous were 0.07 (95% CI, 0.02-0.20; Po0.001) and 0.27 (95% CI, 0.12-0.61; Po0.001), respectively, in white and intermediate individuals. In contrast, the corresponding OR for black Brazilians was 1.34 (95% CI, 0.57-3.17; P ¼ 0.46). The effect of the population subgroups on the OR for the association between smoking dependence and CYP2A6*1B was also observed when only current smokers were compared with nonsmokers (data not shown).
DISCUSSION
This is the first study of CYP2A6 polymorphism and correlation with smoking habits in Brazilians. The present day 180 million Brazilian population is highly admixed, due to five centuries of intercrossing between three main groups, namely native Amerindians, European colonizers and Africans, originally brought into the country as slaves. 24, 30, 31 The population heterogeneity in Brazil compounds ethnic classifications, based on continental origin, racial background or physical appearance. Indeed, studies based on population-specific alleles, blood groups and electrophoresis of protein markers outlined the hazards of equating 'color' or 'race' with geographical ancestry in Brazilians. 24, [30] [31] [32] [33] [34] Furthermore, race is not a constant-a person who is 'black' in the United States may be 'white' in Brazil, where no racial descent rule appears to be operational, and it is possible for two siblings differing in 'color' to belong to diverse racial categories. 24 These observations suggest that ethnic stratification of the Brazilian population for pharmacogenetic studies may be misleading, if not unwarranted, and great caution must be exercised when reviewing pharmacogenetic data from Brazilians in relation to other population groups. These considerations notwithstanding, the present study revealed significant differences in the CYP2A6 allelic distribution across the white, intermediate and black Brazilian subgroups, in which the study population was subdivided following the criteria of the latest Brazilian Census (Materials and methods). Pair-wise comparison within these subgroups indicated a significantly lower frequency of CYP2A6*1B in black vs white Brazilians. The frequency distribution of the variant alleles CYP2A6*1B, *2, *4 and *9 in white and black Brazilians was similar to those reported for European and North-American Caucasians 19 and African-Americans, respectively. There is no available data for comparison of the CYP2A6 alleles and genotypes with the third major root of the present-day Brazilian population, namely South-American Indians. It is worth noting that the gene deletion mutation CYP2A6*4, which accounts for 16-31% of the CYP2A6 alleles in Asians, 19 was detected in only three out of the 342 Brazilians tested, one being homozygous and two heterozygous for this allele.
As several CYP2A6 genotypes were absent or at low frequencies (o1%) in one of more population subgroups, pooled data from the overall study population were used for investigating the influence of CYP2A6 polymorphisms on smoking habits. While statistical analysis pointed to an association between CYP2A6 genotypes and smoking dependence (Table 4) , this could not be explained by reduced or defective activity of CYP2A6 (Table 5 ). The discrepancy of the latter results with previous observations in other populations 14, 16 may be explained by one of two factors: (i) a type 2 error, due to insufficient statistical power, because of the relatively small numbers of individuals having the defective and reduced-activity phenotypes in the present study; (ii) a biological factor, such that the phenotypic activity of the CYP2A6 gene products in the study population is not the only, or the predominant variable, responsible for the observed association between CYP2A6 polymorphism and smoking habits; indeed, there is evidence that smoking behavior is influenced by other genetic factors as well as environmental variables. [2] [3] [4] [5] Further studies with larger population samples might distinguish between these possibilities.
A novel observation of our study is the association of the variant allele CYP2A6*1B with smoking status, which showed a distinct 'ethnic' influence. Thus, in white and intermediate Brazilians, genotypes including at least one copy of CYP2A6*1B were over-represented in nonsmokers, as compared to smokers. The ORs calculated from these data suggested that CYP2A6*1B confers a 14-fold and a three-fold lower probability for being tobacco-dependent in Brazilians self-classified as white and intermediate, respectively. In contrast, no influence of the CYP2A6*1B allele was detected in black Brazilians. The reason for the observed differences across the study subgroups is not clear, especially in view of the extensive miscegenation of Brazilians. However, there are previous examples of the same risk allele for a complex trait being associated with variable outcomes in different population groups. 35 As the CYP2A6*1B allele appears to codify for a normal phenotype, 36 its influence on smoking dependence cannot be ascribed to impaired (CYP2A6-mediated) nicotine metabolism, as proposed for defective CYP2A6 alleles. 14, 15 Nevertheless, it is possible that alleles classified in the present study as CYP2A6*1B contain additional mutations that affect nicotine metabolism, as has been seen before in Asians. 37 Recently, a new polymorphism in the promoter region of the CYP2A6, which is linked to the gene conversion in 3 0 -flanking region, has been reported in Swedish and Turkish individuals, but the activity of the CYP2A6 codified by this variant has not been established 'in vivo'. 38 Finally, the possibility that the gene conversion in the 3 0 -flanking region, which defines the CYP2A6*1B allele is not per se related to smoking status, but is a genetic marker, in linkage disequilibrium with other mutation(s), which affect smoking behavior, cannot be excluded.
The interest of studying CYP2A6 polymorphisms in relation to smoking is not limited to nicotine metabolism, since this enzyme plays a major role in the in vivo activation 17, 18 A related observation is that the risk of lung cancer is reduced in individuals homozygous for allele CYP2A6*1B, 16 which in our study had significant effects on smoking behavior. Taken together, these observations highlight the importance of the pharmacogenetics of CYP2A6 in risk assessment of tobacco product consumers and in developing novel preventive and therapeutic strategies to deal with the problem of drug dependence.
